Citadel Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$90.6M Buy
1,494,234
+471,773
+46% +$27.5M 0.01% 884
2025
Q4
$55.2M Sell
1,022,461
-1,410,082
-58% -$67.8M 0.01% 1326
2025
Q3
$110M Buy
2,432,543
+1,553,792
+177% +$72.6M 0.02% 771
2025
Q2
$40.7M Buy
878,751
+592,598
+207% +$29.1M 0.01% 1403
2025
Q1
$17.5M Buy
286,153
+244,614
+589% +$14.3M ﹤0.01% 2192
2024
Q4
$454K Sell
41,539
-5,044,596
-99% -$282M ﹤0.01% 8770
2024
Q3
$263M Sell
5,086,135
-5,885,542
-54% -$276M 0.05% 280
2024
Q2
$456M Buy
10,971,677
+10,660,102
+3,421% +$477M 0.09% 136
2024
Q1
$16.9M Sell
311,575
-2,674,467
-90% -$136M ﹤0.01% 2263
2023
Q4
$153M Buy
2,986,042
+2,125,298
+247% +$112M 0.03% 464
2023
Q3
$50M Sell
860,744
-327,865
-28% -$20.1M 0.01% 1075
2023
Q2
$76M Buy
1,188,609
+819,242
+222% +$54.9M 0.02% 774
2023
Q1
$25.6M Sell
369,367
-2,710,185
-88% -$191M 0.01% 1681
2022
Q4
$222M Buy
3,079,552
+2,857,109
+1,284% +$215M 0.05% 300
2022
Q3
$15.8M Sell
222,443
-758,746
-77% -$55M ﹤0.01% 2155
2022
Q2
$75.6M Buy
981,189
+584,567
+147% +$44.5M 0.02% 748
2022
Q1
$29M Sell
396,622
-254,136
-39% -$17.1M 0.01% 1588
2021
Q4
$40.6M Sell
650,758
-76,301
-10% -$4.48M 0.01% 1336
2021
Q3
$43M Sell
727,059
-1,332,962
-65% -$87.8M 0.01% 1252
2021
Q2
$138M Sell
2,060,021
-282,516
-12% -$18.4M 0.03% 505
2021
Q1
$148M Buy
2,342,537
+2,232,421
+2,027% +$139M 0.04% 410
2020
Q4
$6.83M Sell
110,116
-6,995,645
-98% -$430M ﹤0.01% 3160
2020
Q3
$428M Buy
7,105,761
+1,081,490
+18% +$65.1M 0.12% 83
2020
Q2
$354M Buy
6,024,271
+4,703,377
+356% +$281M 0.13% 78
2020
Q1
$73.6M Sell
1,320,894
-1,459,837
-52% -$89.2M 0.03% 468
2019
Q4
$178M Buy
2,780,731
+1,767,691
+174% +$101M 0.08% 201
2019
Q3
$51.4M Sell
1,013,040
-3,376,244
-77% -$159M 0.02% 743
2019
Q2
$199M Buy
4,389,284
+1,311,875
+43% +$61.1M 0.09% 165
2019
Q1
$147M Buy
3,077,409
+1,021,015
+50% +$50.9M 0.07% 234
2018
Q4
$107M Sell
2,056,394
-2,022,021
-50% -$109M 0.06% 303
2018
Q3
$253M Sell
4,078,415
-84,614
-2% -$5.02M 0.11% 125
2018
Q2
$230M Sell
4,163,029
-216,798
-5% -$11.7M 0.11% 122
2018
Q1
$277M Sell
4,379,827
-1,487,119
-25% -$95.7M 0.15% 81
2017
Q4
$360M Buy
5,866,946
+3,745,139
+177% +$234M 0.22% 54
2017
Q3
$135M Sell
2,121,807
-119,553
-5% -$6.98M 0.1% 164
2017
Q2
$125M Buy
2,241,360
+1,368,028
+157% +$74.4M 0.11% 170
2017
Q1
$47.5M Sell
873,332
-105,605
-11% -$5.79M 0.04% 482
2016
Q4
$57.2M Sell
978,937
-860,893
-47% -$47.1M 0.06% 330
2016
Q3
$99.2M Sell
1,839,830
-2,466,371
-57% -$158M 0.1% 167
2016
Q2
$317M Sell
4,306,201
-714,254
-14% -$50.5M 0.35% 29
2016
Q1
$321M Buy
5,020,455
+478,740
+11% +$30.2M 0.4% 22
2015
Q4
$312M Sell
4,541,715
-2,510,092
-36% -$166M 0.34% 31
2015
Q3
$417M Buy
7,051,807
+3,074,227
+77% +$195M 0.4% 23
2015
Q2
$265M Sell
3,977,580
-164,624
-4% -$10.8M 0.23% 61
2015
Q1
$267M Buy
4,142,204
+3,238,388
+358% +$203M 0.25% 56
2014
Q4
$53.4M Buy
903,816
+363,093
+67% +$20.5M 0.05% 442
2014
Q3
$27.7M Sell
540,723
-1,280,718
-70% -$64M 0.03% 720
2014
Q2
$88.4M Sell
1,821,441
-1,456,553
-44% -$71.8M 0.1% 194
2014
Q1
$170M Sell
3,277,994
-2,897,873
-47% -$154M 0.2% 69
2013
Q4
$328M Buy
6,175,867
+6,170,686
+119,102% +$314M 0.43% 14
2013
Q3
$240K Sell
5,181
-595,905
-99% -$26.2M ﹤0.01% 4584
2013
Q2
$26.9M Buy
+601,086
New +$26.1M 0.05% 494

Other funds holding BMY

Citadel Advisors's BMY Position: Q1 2026 in Review

Citadel Advisors increased its Bristol-Myers Squibb (BMY) stake by 46% in Q1 2026, buying an estimated $27.5M and bringing the position to 1,494,234 shares worth $90.6M. The position accounts for 0.01% of the portfolio, ranked #884.

Citadel Advisors first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $456M in Q2 2024. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Citadel Advisors held 1,494,234 shares of Bristol-Myers Squibb worth $90.6M as of Q1 2026.
  • Citadel Advisors bought 471,773 Bristol-Myers Squibb shares in Q1 2026, an estimated $27.5M.
  • Bristol-Myers Squibb made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #884 holding.
  • Citadel Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Bristol-Myers Squibb position peaked at $456M in Q2 2024.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.